Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire - A cross-protocol analysis

被引:120
作者
Reynolds, Nancy R.
Sun, Junfeng
Nagaraja, Haikady N.
Gifford, Allen L.
Wu, Albert W.
Chesney, Margaret A.
机构
[1] Yale Univ, New Haven, CT 06536 USA
[2] Ohio State Univ, AIDS Clin Trials Unit, Columbus, OH 43210 USA
[3] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA
[4] Ohio State Univ, Dept Stat, Columbus, OH USA
[5] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA
[6] Johns Hopkins Bloomberg, Dept Hlth Policy & Management, Baltimore, MD USA
[7] Natl Ctr Complement & Alternat Med, Bethesda, MD USA
关键词
adherence; AIDS clinical trials group; index; measurement;
D O I
10.1097/QAI.0b013e318158a44f
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background/Objective: The AIDS Clinical Trials Group (ACTG) Adherence Questionnaire is used extensively, but investigators frequently only use the first item of the questionnaire (4-day recall). Design/Methods: A secondary analysis was conducted to (1) estimate the validity and reliability of each of the 5 scale iterns and (2) compare the approach commonly used to summarize adherence data collected with the instrument (average 4-day recall) with alternate approaches derived using principal component (PC) analysis and the full questionnaire. We hypothesized that an estimate of adherence taking all items of the questionnaire into account would provide a stronger measure of adherence. Results: Logistic regression analyses showed that the first PC identified (PCl) was significantly correlated with plasma HIV RNA outcome (P < 0.0001 for ACTG 370 data and P = 0.006 for ACTG 398 data) and correlated with plasma HIV RNA better than average 4-day recall. An adherence index formulated using weights of PCl showed substantially greater variability in the range of adherence scores in comparison to average 4-day adherence recall alone. PCl compared favorably with 2 indices derived from medication event monitoring system data as well. Conclusions: Findings indicate that a superior assessment of antiretroviral adherence may be obtained with the ACTG Adherence Questionnaire by using the method employed in this analysis.
引用
收藏
页码:402 / 409
页数:8
相关论文
共 14 条
[1]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[2]   Factors associated with nonadherence to highly active antiretroviral therapy -: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase [J].
Carrieri, MP ;
Leport, C ;
Protopopescu, C ;
Cassuto, JP ;
Bouvet, E ;
Peyramond, D ;
Raffi, F ;
Moatti, JP ;
Chêne, G ;
Spire, B .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (04) :477-485
[3]   Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments [J].
Chesney, MA ;
Ickovics, JR ;
Chambers, DB ;
Gifford, AL ;
Neidig, J ;
Zwickl, B ;
Wu, AW .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (03) :255-266
[4]  
Dal Fabbro Márcia Maria Ferrairo Janini, 2005, Braz J Infect Dis, V9, P20, DOI 10.1590/S1413-86702005000100005
[5]   Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection [J].
Gulick, RM ;
Ribaudo, HJ ;
Shikuma, CM ;
Lustgarten, S ;
Squires, KE ;
Meyer, WA ;
Acosta, EP ;
Schackman, BR ;
Pilcher, CD ;
Murphy, RL ;
Maher, WE ;
Witt, MD ;
Reichman, RC ;
Snyder, S ;
Klingman, KL ;
Kuritzkes, DR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) :1850-1861
[6]   Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection - A randomized controlled trial [J].
Gulick, Roy M. ;
Ribaudo, Heather J. ;
Shikuma, Cecilia M. ;
Lalama, Christina ;
Schackman, Bruce R. ;
Meyer, William A., III ;
Acosta, Edward P. ;
Schouten, Jeffrey ;
Squires, Kathleen E. ;
Pilcher, Christopher D. ;
Murphy, Robert L. ;
Koletar, Susan L. ;
Carlson, Margrit ;
Reichman, Richard C. ;
Bastow, Barbara ;
Klingman, Karin L. ;
Kuritzkes, Daniel R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (07) :769-781
[7]   Dual vs single protease inhibitor therapy following antiretroviral treatment failure - A randomized trial [J].
Hammer, SM ;
Vaida, F ;
Bennett, KK ;
Holohan, MK ;
Sheiner, L ;
Eron, JJ ;
Wheat, LJ ;
Mitsuyasu, RT ;
Gulick, RM ;
Valentine, FT ;
Aberg, JA ;
Rogers, MD ;
Karol, CN ;
Saah, AJ ;
Lewis, RH ;
Bessen, LJ ;
Brosgart, C ;
DeGruttola, V ;
Mellors, JW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :169-180
[8]  
Hosmer W., 2000, Applied Logistic Regression, VSecond
[9]   Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370 [J].
Kuritzkes, DR ;
Bassett, RL ;
Johnson, VA ;
Marschner, IC ;
Eron, JJ ;
Sommadossi, JP ;
Acosta, EP ;
Murphy, RL ;
Fife, K ;
Wood, K ;
Bell, D ;
Martinez, A ;
Pettinelli, CB .
AIDS, 2000, 14 (11) :1553-1561
[10]  
Little R. J., 2019, STAT ANAL MISSING DA, V793, DOI DOI 10.1002